ArticleNoise & health
Maternal Gestational Diabetes Mellitus as an Independent Risk Factor for Hearing Impairment in Hyperbilirubinemia Newborns: A Prospective Birth Cohort With Genetic Profiling.
Article in Noise & health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGestational diabetes mellitus (GDM) may exacerbate hyperbilirubinemia-induced auditory neurotoxicity via oxidative stress, whereas genetic susceptibility (e.g., GJB2 variants) heightens cochlear vulnerability. However, the tripartite interplay among maternal metabolic dysregulation, neonatal hyperbilirubinemia and genetic predisposition remains poorly characterized.
objectiveThis study aimed to investigate the synergistic interaction between GDM and neonatal hyperbilirubinemia in auditory dysfunction, focusing on the modifying role of deafness-associated genetic variants (GJB2, SLC26A4, and mtDNA).
methodsIn this prospective cohort study (our hospital, 2023-2025), 350 neonates were classified by an exposure-based 2 × 2 factorial design into four groups: GDM-exposed hyperbilirubinemia ( n = 98), non-GDM hyperbilirubinemia ( n = 185), GDM-only ( n = 42) and healthy controls ( n = 25). Genetic screening was performed via Sanger sequencing. Serial audiological assessments (automated auditory brainstem response) and brainstem auditory evoked potential [BAEP]) and biochemical monitoring (bilirubin-to-albumin [B/A]), malondialdehyde [MDA] and superoxide dismutase) were conducted at birth, 72 h, 1 month, and 3 months. Cox proportional hazards models, multivariable logistic regression and bootstrapped causal mediation analysis were used to evaluate risk factors and oxidative stress-mediated pathways.
resultsGDM-exposed hyperbilirubinemia neonates exhibited a 2.3-fold higher incidence of severe hearing loss compared with those with hyperbilirubinemia alone (34.7% vs. 15.1%, P < 0.001). GJB2 variant carriers showed significantly greater BAEP threshold elevation (Δ = 9.2 ± 3.1 dB vs. 3.1 ± 1.8 dB, P = 0.002) than their counterparts. The B/A ratio was a GDM-dependent prognostic marker, with B/A > 5.5 predicting hearing loss only in the GDM subgroup (odds ratio = 4.17, 95% confidence interval [CI]: 2.33-7.45). MDA accounted for 38% of the total effect of GDM-hyperbilirubinemia on auditory impairment (indirect effect β = 0.28, 95% CI: 0.19-0.39).
conclusionGDM significantly modifies hyperbilirubinemia-induced auditory toxicity through oxidative stress and genetic interaction, particularly in GJB2 carriers. Integrated screening of maternal glycemic status, neonatal bilirubin dynamics, and deafness-associated genes is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.